GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » NonCurrent Deferred Liabilities

Spexis AG (XSWX:SPEX) NonCurrent Deferred Liabilities : CHF0.00 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Spexis AG's non-current deferred liabilities for the quarter that ended in Dec. 2023 was CHF0.00 Mil.

Spexis AG NonCurrent Deferred Liabilities Historical Data

The historical data trend for Spexis AG's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG NonCurrent Deferred Liabilities Chart

Spexis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Spexis AG Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Spexis AG NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Spexis AG's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Spexis AG (XSWX:SPEX) Business Description

Industry
Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines